Study of ABSK061 for children with achondroplasia
Part of Bones, joints & muscles, Genetic & congenital clinical trials.
This trial tests a new medicine (ABSK061) for children with achondroplasia, a common form of dwarfism. It aims to see if the drug is safe and can help with growth. Children age 3 to under 12 may qualify.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have achondroplasia confirmed by genetic testing.
- Your age is between 3 and under 12 years old (specific groups based on exact age).
- You have been in a previous observation study for at least 6 months and have had your growth tracked.
- You have not started puberty (Tanner stage 1).
- Your bone age (from hand X-ray) is less than 14 years.
- You have not taken other treatments for growth (like growth hormone) in the past year or certain other drugs ever.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medicine for children with achondroplasia (a common form of dwarfism). It aims to see if the drug can improve growth. The study is for children aged 2.5 to under 11 years old who have not started puberty and can walk without help.
This trial tests a new medicine (KK8398) for children with achondroplasia (a common cause of dwarfism). It aims to see if the medicine can help improve bone growth and safety. It may be a good option for children who haven't yet reached their final height and haven't been treated with other growth therapies.
This study tests an experimental oral medication (TYRA-300) for children with achondroplasia, a common form of dwarfism. The goal is to see if it can safely improve growth in children whose growth plates are still open.
This trial tests a weekly injection called navepegritide for adolescents aged 12-18 with achondroplasia (a common form of dwarfism). The goal is to see if it can safely improve growth. You must have a genetic confirmation of achondroplasia and a historical height measurement from the past 6 to 15 months.
This trial tests a new medicine, BMN 333, against an existing one (vosoritide) to see if it helps children with achondroplasia grow. It's for kids who haven't used these treatments before.
This trial tests an oral medication called infigratinib to see if it can help young children with achondroplasia. It is for children under 3 years old who have a confirmed genetic diagnosis.
Hear when a new Achondroplasia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.